Compositions comprising albumin-fms-like tyrosine kinase 3 ligand fusion proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-2022211811-A1
Application number	US-202117561606-A
Country	US
Kind code	A1
Filing date	Dec 23, 2021
Priority date	Jan 10, 2018
Publication date	Jul 7, 2022
Grant date	—

Abstract

The present invention provides a novel fusion protein of Flt3L and albumin and its use to increase the Flt3L half-life in vivo and to deliver Flt3L to immune cells in a subject to enhance alternative dendritic cell populations. Use of the fusion protein in combination with other chemotherapeutic, radiotherapeutic and immunotherapeutic methods are also provided.

First claim

1 - 14 . (canceled)

15 . A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising a polypeptide encoding albumin protein linked to a polypeptide encoding Flt3L protein.

16 . The method of claim 15 , wherein the method further comprises administering to the subject an effective amount of at least one additional chemotherapeutic agent.

17 . The method of claim 15 , wherein the method further comprises administering to the subject an effective amount of an immunotherapeutic agent.

18 . The method of claim 17 , wherein the immunotherapeutic agent is a PD-1 inhibitor.

19 . The method of claim 15 , wherein the method further comprises administering to the subject an effective amount of radiation therapy.

20 . The method of claim 19 , wherein the radiation therapy is focused radiation therapy.

21 . The method of claim 20 , wherein the amount of radiation given is between about 1 gy to about 30 gy.

22 . The method of claim 15 , wherein the albumin protein is human.

23 . The method of claim 15 , wherein the Flt3L protein is human.

24 . The method of claim 15 , wherein the albumin protein is murine.

25 . The method of claim 24 , wherein the Flt3L protein is murine.

26 . The method of claim 15 wherein the polypeptide comprises a sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1.

27 . The method of claim 15 wherein the polypeptide comprises a sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 1.

28 . The method of claim 15 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1.

29 . The method of claim 24 wherein the composition has the amino acid sequence of SEQ ID NO: 2.

30 . The method of claim 24 wherein the composition has the amino acid sequence of SEQ ID NO: 3.

Assignees

• Univ Johns Hopkins

Inventors

• Wu T C
• Hung Chien-Fu
• Lam Brandon

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C12N15/62

  DNA sequences coding for fusion proteins · CPC title

• C07K19/00

  Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes} · CPC title

• C07K2319/31

  fusions, other than Fc, for prolonged plasma life, e.g. albumin · CPC title

• A61N5/00

  Radiation therapy (ultrasound therapy A61N7/00; devices or apparatus applicable to both therapy and diagnosis A61B6/00) · CPC title